Rezolute, Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation NV
Business Address 275 SHORELINE DRIVE, SUITE 500, REDWOOD CITY, CA, 94065
Mailing Address 275 SHORELINE DRIVE, SUITE 500, REDWOOD CITY, CA, 94065
Phone 650-206-4507
Fiscal Year End 0630
EIN 273440894
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | February 13, 2026 | View on SEC |
| 8-K Current report of material events | February 12, 2026 | View on SEC |
| 10-Q Quarterly financial report | February 12, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | February 11, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | January 30, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | January 8, 2026 | View on SEC |
| 8-K Current report of material events | January 7, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | December 19, 2025 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | December 18, 2025 | View on SEC |
| 4 Insider stock transaction report | December 17, 2025 | View on SEC |
Annual Reports
10-K September 17, 2025
- RZ358 (for rare diabetes complication) advanced to final stage of human testing
- FDA granted priority review status for RZ358, speeding up potential approval
Material Events
8-K Other January 7, 2026
High Impact
- Rezolute, Inc. released new 'further insights' from its sunRIZE clinical trial for ersodetug.
- Detailed data from the first 9 patients in the Expanded Access Program (EAP) for ersodetug was also provided.
Insider Trading
BUY 5 insiders
8 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.